Investment Research and Business Due Diligence
Thursday, April 25, 2013
Bristol Myer initates a bioequivalence study to evaluate a fixed dose combination of Reyataz and Cobicistat
The trial has been initiated as result of an agreement between Bristol-Myers Squibb and Gilead to collaborate on the development of a new once-daily fixed-dose coformulation containing the widely used HIV protease inhibitor atazanavir (Reyataz) plus Gilead's novel pharmacoenhancer cobicistat. Currently atazanavir is typically boosted with a low dose of ritonavir (Norvir) taken as a separate pill. Cobocistat is yet not approved by the USFDA. The PDUFA is on April 28, 2013.
Bristol-Myers Squibb will be responsible for the formulation, manufacturing, development, registration, distribution, and commercialization of the Reyataz and cobicistat fixed-dose combination worldwide. Under the terms of the agreement, Bristol-Myers Squibb will pay Gilead an undisclosed royalty based on annual net sales of the product. Gilead retains sole rights for the manufacture, development and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.
Enter your email address:
Share to Twitter
Share to Facebook
Share to Pinterest
Post Comments (Atom)